Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03652727
Other study ID # 2018-00907
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 4, 2018
Est. completion date February 20, 2019

Study information

Verified date January 2020
Source University of Lausanne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to compare two techniques of placing a peripherally inserted central venous catheter (PICC). The first technique, uses ECG based electromagnetic guidance (ECG-EM). The second (reference technique), is guided by X-ray (fluoroscopy).


Description:

The method of placement under fluoroscopic control (FX) is considered as the reference technique. This is often criticized for disadvantages such as costs, logistical problems and relative ionizing radiation. Despite this, it is still advised by 75% of PICC providers.

Appeared about ten years ago, a per procedural guiding technique with intracavitary ECG tracking (ECG-EM) presents a better technical success (precision and specificity) than the blind technique, but there is still a lack in comparing this technique to the FX technique.

This prospective randomized controlled study is designed to compare the PICC insertion using ECG-EM guidance to fluoroscopic (FX) guidance in order to define whether a replacement of the FX technique by ECG-EM is appropriate in terms of the final catheter tip position of the PICC as well as length of the outgoing catheter at the entry point.

All included patients gave their written consent and the study is approved by EC.

Participation is open to all adults referred to the radiology department of the CHUV for insertion of a PICC (monocentric).

Recruited patients will be randomly assigned to one of the two arms (FX or ECG-EM).

For both procedures patient position and preparation (MSB, maximal sterile barrier) are standardized and are similar.

FX method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. Through the point of puncture, a long wire is then introduced and directed to the level of the target zone located in the superior vena cava under fluoroscopy control. The length of the guide inside the vessel is then measured to adjust the length of the PICC necessary for its optimal positioning.

For ECG-EM insertion technique, the vein puncture is done in similar conditions to the FX method. The length of the PICC is estimated prior to its insertion using morphological landmarks. The placement of the PICC is done using SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) (CE marked device; C. R. Bard, Inc.).

At the end of procedure, a chest x-ray is performed to assess the PICC position. Possible per-procedural complications are documented.

After intervention, the patient is transferred back to the ward or sent home in stable conditions.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date February 20, 2019
Est. primary completion date November 8, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Informed Consent as documented by signature (Informed Consent Form)

- Adult > 18 years

- Referred to the interventional radiology department for PICC insertion

Exclusion Criteria:

- Pregnant women

- Known or suspected non-compliance

- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,

- Previous enrolment into the current study,

- Enrolment of the investigator, his/her family members, employees and other dependent persons,

- Impairment of the heart rhythm changing the presentation of the P wave (atrial fibrillation, atrial flutter, severe tachycardia, pacemaker driven rhythm)

- Enrolled in conflicting research study

- Weight> 150 kg, technical limit for the fluoroscopy table

- Impossibility of obtaining informed consent

Study Design


Intervention

Device:
ECG-EM Guidance
ECG-EM method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. The length of the PICC is estimated prior to its insertion using morphological landmarks. The placement of the PICC is done using SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) [CE marked device, C. R. Bard, Inc.]. At the end of procedure, a chest x-ray is performed to assess the PICC position
FX Guidance
FX method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. Through the point of puncture, a long wire is then introduced and directed to the level of the target zone located in the superior vena cava under fluoroscopy control. The length of the guide inside the vessel is then measured to adjust the length of the PICC necessary for its optimal positioning. At the end of procedure, a chest x-ray is performed to assess the PICC position

Locations

Country Name City State
Switzerland CHUV Lausanne Vaud

Sponsors (2)

Lead Sponsor Collaborator
Salah D. Qanadli Centre Hospitalier Universitaire Vaudois

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tip to CAJ (Cavo-atrial junction) At the end of intervention tip position is measured on chest fluoroscopic X-ray.
Absolute distance from tip to CAJ is measured on the image. This will reflect proportions of optimal tip positions depending on guidance technology.
Rationale is that optimal position is mandatory for adequate functioning of PICC as malpositions may result on cardiac rhythm disorders, thrombosis or premature PICC occlusion.
Up to 1 hour, after the procedure
Secondary Length of the outgoing catheter Length of the outgoing catheter at the entry point near the bend of the elbow. The rationale behind is that correct positioning guarantees optimal haemostasis and might prevent secondary displacement Up to 1 hour, after the procedure
Secondary Inter-observer and intra-observer variance The CAJ to catheter tip distance is based on subjective assessment by one investigator of the X-ray chest. Rationale behind is that in order to evaluate the impact of potential variation due to subjective interpretation interobserver and intraobserver variance will be quantified Through study completion, an average of 9 month
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05856656 - Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer N/A
Active, not recruiting NCT02959541 - PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer N/A
Completed NCT00757094 - Safety and Feasibility of Fasting While Receiving Chemotherapy N/A
Recruiting NCT00797238 - DNA Repair Genes and Outcomes in Patients With Stage III NSCLC N/A
Not yet recruiting NCT05927857 - Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . Phase 1/Phase 2
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Completed NCT04466332 - Comparison of Two ECG Guided PICC Insertion Techniques N/A
Not yet recruiting NCT04055038 - Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) Phase 2/Phase 3
Recruiting NCT03701607 - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting NCT04024241 - Medium Dose of Cytarabine and Mitoxantrone
Recruiting NCT06208436 - The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
Recruiting NCT05306301 - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Phase 2
Active, not recruiting NCT02304640 - Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
Completed NCT02298972 - Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer N/A
Terminated NCT01249001 - Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents Phase 2
Recruiting NCT03089892 - A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy N/A
Recruiting NCT05125055 - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC Phase 2/Phase 3
Recruiting NCT04472403 - Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
Terminated NCT02982694 - Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer Phase 2
Completed NCT03261128 - Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment.(D-FOG)